FDA Output, February 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in February 2026. Updated February 23.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in February 2026. Updated February 23.
MedTech Innovator cohort companies RIVANNA, IMVARIA, and Anumana apply AI-driven solutions across a range of medical specialties.
Pulsed field ablation is set to supplant radiofrequency and cryoablation as the preferred catheter-based approach to stopping arrhythmias. Because it is safer and faster than older technologies, it is helping electrophysiologists treat more patients and accelerate the overall growth of the cardiac ablation business. Excerpted from our recent feature, "PFA Is Ready to Electrify the Electrophysiology Market."